LifeSciences BC > News > Industry News > 2014 > Biotechnology Focus – Qu Biologics granted broad Australian Patent for targeted treatment of multiple cancers

B.C. Industry News

Biotechnology Focus – Qu Biologics granted broad Australian Patent for targeted treatment of multiple cancers

January 28, 2014

Qu Biologics has been granted its second broad Australian patent for the targeted treatment of a number of cancers, including all common cancers.

“Immunotherapies represent a paradigm shift in the treatment of cancer by focusing on the immune response rather than the tumour,” commented Dr. Hal Gunn, CEO of Qu Biologics. “Qu Biologics is at the forefront of immunotherapy treatment that ‘reboots’ the body’s innate immune system and this second broad patent allows us to protect and further extend our strong position in immunotherapy research and the development of our site specific immunomodulators.”

The biopharmaceutical company was issued Australian Patent No.2007308721. The granted patent involves the tissue-targeted activation of the immune response to treat cancers. The patent includes formulations of killed viruses to stimulate this site specific anti-tumour immune response.

Qu Biologics is developing immunotherapies, called Site Specific Immunomodulators (SSIs),   from inactivated bacteria and viruses. SSIs aim to reboot the body’s own immune system to treat cancer and autoimmune disease. The company’s SSI platform represents a promising new approach to cancer and autoimmune disease. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.